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Katja-Martina Eckl1, Silvia de Juanes2, Janine Kurtenbach1, Marc Na¨tebus1, Jenny Lugassy3,4,5, Vinzenz Oji6,
Heiko Traupe6, Marie-Luise Preil7, Francisco Martı´nez8, Josef Smolle9, Avikam Harel10, Peter Krieg2,
Eli Sprecher3,4,5 and Hans C. Hennies1,11
In recent years several new genes for autosomal recessive congenital ichthyosis (ARCI) have been identified.
However, little is known about the molecular epidemiology and pathophysiology of this genetically and
clinically heterogeneous group of severe disorders of keratinization. ARCI is characterized by intense scaling of
the whole integument often associated with erythema. We and others have shown that mutations in ALOX12B
and ALOXE3, coding for the lipoxygenases 12R-LOX and eLOX-3 predominantly synthesized in the epidermis,
can underlie this rare condition. Here we have surveyed a large group of 250 patients with ARCI for mutations in
these two genes. We have identified 11 different previously unreported mutations in ALOX12B and ALOXE3 in 21
ARCI patients from 19 unrelated families and demonstrated that mutations in the two genes are the second
most common cause for ARCI in this cohort of patients. Examination of the molecular data revealed allelic
heterogeneity for ALOX12B and two mutational hotspots in ALOXE3. Functional analysis of all missense
mutations and a splice site mutation demonstrated that complete loss of function of the enzymes underlies the
phenotype. Our findings further establish the pivotal role of the 12-lipoxygenase pathway during epidermal
differentiation.
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INTRODUCTION
Lipoxygenases (LOX) represent a widely distributed family of
non-heme, iron-containing dioxygenases that catalyze the
regioselective and stereoselective dioxygenation of fatty acid
substrates containing one or more (Z,Z)-1,4-pentadiene
moieties (reviewed by Brash, 1999; Ku¨hn and Thiele,
1999). Within the mammalian LOX family, a distinct subclass
of epidermis-type LOX has been found to be preferentially
synthesized in the skin and few other epithelial tissues (Brash
et al., 1997, 2007; Boeglin et al., 1998; Kinzig et al., 1999;
Heidt et al., 2000; Krieg et al., 2002). The genes for the
human epidermal LOX, 15-LOX-2, 12R-LOX, and eLOX-3,
map closely together on human chromosome 17p13.1 (Krieg
et al., 2001). Their differentiation-dependent expression
pattern in epithelial tissues suggests a common physiological
role in the regulation of proliferation and differentiation of
epithelial cells, especially keratinocytes. The epidermal
12R-LOX and eLOX-3 differ from all other mammalian LOX
in their unique structural and enzymatic features (Boeglin
et al., 1998; Kinzig et al., 1999; Krieg et al., 1999) as both
proteins contain an extra domain located at the surface of the
catalytic subunit. 12R-LOX represents the only mammalian
LOX that forms products with R chirality, and, unlike all other
LOX, eLOX-3 does not exhibit dioxygenase activity but acts
as a hydroperoxide isomerase (Yu et al., 2003). Both enzymes
participate in the same pathway and convert arachidonic
acid via 12R-hydroperoxy-5Z,8Z,10E,14Z-eicosatetraenoic
acid (12R-HPETE) to the corresponding hepoxilin-like
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Mutations in ALOX12B and ALOXE3, the genes for 12R-LOX
and eLOX-3, were found in patients with autosomal recessive
congenital ichthyosis (ARCI; Jobard et al., 2002; Eckl et al.,
2005). We and others have shown that those mutations
completely eliminate the catalytic activity of the LOX
enzymes, suggesting that mutational inactivation of either
12R-LOX or eLOX-3 is causally linked to the ARCI phenotype
(Eckl et al., 2005; Yu et al., 2005). Furthermore, 12R-LOX
deficiency in the mouse clearly recapitulates the human
phenotype (Epp et al., 2007; Moran et al., 2007).
ARCI, including lamellar ichthyosis, non-bullous conge-
nital ichthyosiform erythroderma, and congenital fine scal-
ing, forms a clinically and genetically heterogeneous group of
severe keratinization disorders with a prevalence of approxi-
mately 1 in 200,000 persons in the European and northern
American populations (Traupe, 1989; Williams et al., 2005;
Oji and Traupe, 2006; Schmuth et al., 2007). Affected
newborns often present with a so-called collodion mem-
brane. After loss of this encasement in the first weeks of life,
patients exhibit a generalized scaling, which varies from
patient to patient in extent, color, and degree of adherence.
An underlying erythema is often seen, but mostly mild.
Further features may include alopecia, hypohydrosis, as well
as marked hyperlinearity and hyperkeratosis of the palms and
soles. Although mutations in six genes, TGM1, ALOX12B,
ALOXE3, ABCA12, Ichthyin, and CYP4F22, have been found,
more loci must exist, as 30–40% of all ARCI patients do not
have mutations in any of these genes. Only transglutaminase
1, 12R-LOX, and eLOX-3, the products of TGM1, ALOX12B,
and ALOXE3, respectively, have been analyzed functionally
so far, and only the pathophysiology of ARCI caused by
deficiency of transglutaminase 1 has been analyzed in more
detail.
Here we present 11 previously unreported inactivating
mutations in either ALOX12B or ALOXE3, seen in 19
independent ARCI cases out of 250 patients analyzed. In
contrast to ALOX12B, showing extended allelic heterogene-
ity, we have identified two mutational hotspots in ALOXE3.
Using an in vitro assay, we have further demonstrated the
ablation of enzyme activity of mutant 12R-LOX and eLOX-3.
RESULTS
Mutation analysis in ALOX12B and ALOXE3
Consanguineous families were prescreened for regions of
homozygosity as described elsewhere (Mizrachi-Koren et al.,
2005; Lugassy et al., 2008). After analyzing TGM1 by direct
sequencing, mutation analysis was extended by sequencing
all 30 exons and exon/intron boundaries of ALOX12B and
ALOXE3. In a series of 250 patients, we identified mutations
in ALOX12B or ALOXE3 in a total of 17 patients each. We
found eight different mutations in ALOX12B previously
unreported to our knowledge, of which two were insertions,
two deletions, two missense mutations, one splice-site
mutation (which we found in two independent patients),
and one mutation of the initial methionine codon (Table 1). In
ALOXE3, two new deletions and one exonic splice site
mutation were detected. In three patients, the second
mutation remained undetected as we expect compound
heterozygosity for those patients, and may reside in
regulatory regions or farther in the introns or represent larger
deletions. All mutations were excluded from a panel of 100
matched control persons.
Patient ISA carried two homozygous missense mutations
in ALOXE3, predicted to result in p.Arg145His and
p.Leu237Met, respectively. Both mutant enzymes, however,
were shown to be enzymatically active (Eckl et al., 2005). We
then tested a double mutant, which also showed normal LOX
activity. As the first mutation, c.434G4A, altered the last
base of exon 3 and prediction of splice sites (Reese et al.,
1997; Nalla and Rogan, 2005) suggested an effect on RNA
splicing, we used a mini-gene assay to analyze the RNA. We
cloned genomic DNA of the patient spanning intron 1 to
exon 5 of ALOXE3 into a eukaryotic expression vector and
transfected the construct into HEK 293 cells. Analysis of total
RNA revealed that the mutation c.434G4A leads to
complete skipping of exon 3 (Figure 1). A second, hetero-
zygous splice site mutation, c.1654þ3A4G in ALOX12B,
was seen in two unrelated patients. Again, tissue samples
from these patients were not available, however, the
mutation alters one of the highly conserved intronic residues
of the donor splice site. The probability for correct splicing is
clearly reduced as predicted by neural network analysis
(Reese et al., 1997). The mutation c.1A4G destroys the
translation start codon. Still an alternative start site may be
used, however, there are only two further potential start sites,
as confirmed upon prediction with NetStart (Pedersen and
Table 1. Summary of previously unreported mutations
in ALOX12B and ALOXE3 including two hotspot
mutations identified in patients with ARCI in this study
Mutation Protein Exon Frequency1
ALOX12B
c.1A4G p.Met1? 1 1
c.583T4C p.Phe195Leu 5 1
c.942_943insTTTA p.Ala316ProfsX59 8 1
c.1144A4G p.Lys382Glu 9 1
c.1153delG p.Val385TyrfsX30 9 1
c.1272_1273insC p.Lys425GlnfsX24 9 1
c.1625_1626delAA p.Lys542ArgfsX13 12 2
c.1654+3A4G splice defect 12 2
ALOXE3
c.434G4A p.Arg119GlyfsX12 3 2
c.700C4T2 p.Arg234X 6 11
c.719delA p.Lys240ArgfsX40 6 1
c.1031_1039del9 p.Gln344_Ala347delinsPro 8 2
c.1889C4T3 p.Pro630Leu 14 15
1Number of independent chromosomes with the mutation identified in
250 ARCI patients described here and by Eckl et al., 2005.
2Mutation described previously by Jobard et al., 2002.
3Mutation described previously by Eckl et al., 2005.
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Nielsen, 1997), at positions 257 and 313 bases downstream
of nucleotide c.1, resulting in a frameshift and in an almost
complete loss of the N-terminal LH2 domain, respectively. In
both cases, the mutation was expected to result in the
synthesis of a nonfunctional peptide.
Analysis of recurrent mutations
Additionally, we found the previously reported mutations
p.Arg234X and p.Pro630Leu of ALOXE3 (Jobard et al., 2002;
Eckl et al., 2005) in 10 unrelated families from Germany: 4
patients were compound heterozygous for both mutations, 2
and 3, respectively, were homozygous for either p.Arg234X
or p.Pro630Leu, and 1 patient was compound heterozygous
for mutations p.Pro630Leu and p.Lys240ArgfsX4. Thus, we
found the mutation p.Arg234X on 8 and the mutation
p.Pro630Leu on 11 independent chromosomes, in addition
to the patients described earlier.
To search for a common origin of these two mutations, we
performed microsatellite marker analysis around the LOX
gene cluster (Krebsova´ et al., 2001; Lugassy et al., 2008) with
all families carrying at least one of the two mutations but did
not detect a shared haplotype. The analysis showed homo-
zygosity for patients FE7 and FE10 but no common haplotype.
Phenotype
A total of 21 patients from 19 unrelated families, originating
from Germany, Austria, Spain, Belgium, Israel, the United
Arab Emirates, and Sri Lanka, were clinically assessed in
detail. These patients carried previously unreported muta-
tions in ALOX12B or ALOXE3; moreover, we have included
our patients with recurrent mutations p.Arg234X and
p.Pro630Leu in ALOXE3. Consanguinity was only reported
for families FE1, FB2, and ISA. Neonates born with collodion
membrane often showed a mild to moderate manifestation
compared with other types of congenital ichthyosis. Ectro-
pion or eclabion, mostly mild, was only present in one-third
of the cases. Children and adults showed a generalized
scaling with mild to moderate erythema. Scales were mostly
whitish to light brown, discrete to moderate in adherence,
and small in size (Figure 2a). Moreover, more than half of the
patients (13 out of 19 patients) showed a striking palmo-
plantar hyperlinearity with or without mild keratoderma
(Figure 2b). In contrast to ichthyosis vulgaris, patients showed
a mild keratotic lichenification that also included the elbow
or popliteal fossa and the dorsa of the extremities (Figure 2c
and d). Heat intolerance because of a reduced sweating
ability (hypohidrosis) was an accompanying clinical problem
in almost all patients. One patient showed a peculiar kink of
the external ear helix (Figure 2e). The clinical features are
summarized in Table S1.
Enzymatic activity of 12R-LOX and eLOX-3
All three new missense mutations found in ALOX12B and the
in-frame deletion c.1031_1039del9 in ALOXE3 were cloned
by site-directed mutagenesis and expressed in HEK 293 cells.
Sonic homogenates were adjusted after Western blot analysis
and incubated with their genuine substrates, that is,
arachidonic acid for 12R-LOX and 12R-HPETE in case of
eLOX-3. 12R-LOX converts arachidonic acid to the primary
product 12R-HPETE, which is rapidly transformed to its
reduced derivative, 12R-HETE; eLOX-3 converts 12R-HPETE
to 8R-hydroxy-11R,12R-epoxyeicosa-5Z,9E,14Z-trienoic acid.
RP-HPLC analyses of incubations with 12R-LOX mutants
revealed no reaction products, similar to extracts from cells
expressing b-galactosidase, indicating complete loss of
enzymatic activity for all 12R-LOX mutants (Figure 3a).
Correspondingly, the in-frame deletion in eLOX-3 resulted in
complete loss of enzyme activity (Figure 3b). The insertions
and deletions that result in a frameshift are supposed to be
deleterious and have therefore not been tested for enzyme
activity.
DISCUSSION
Since the first publication of mutations in ALOX12B and
ALOXE3 describing a total of 6 mutations in patients with
non-bullous congenital ichthyosiform erythroderma from the
Mediterranean area (Jobard et al., 2002), 21 further mutations
in ALOX12B and 3 mutations in ALOXE3 have been
published so far (Figure 4; Table S2; Eckl et al., 2005; Ashoor
et al., 2006; Lesueur et al., 2007; Harting et al., 2008). Here
we have completed the first analysis of ALOX12B and
ALOXE3 in a large group of patients representing the whole
phenotypic spectrum of ARCI. In a total of 250 independent
patients, mutations in TGM1 accounted for 38% of the ARCI
cases (data not shown), and mutations in ALOX12B and
Genomic DNA
Patient ISA
c.434G>A
Wild-type mRNA
mutant mRNA
Pa Pa Co Co D N M
G
Exon 2
Exon 2
Control
Exon 3
Exon 4
G GT
T
CC
C C C
G
GGG
A
A A A A A A A
A A A A A
Figure 1. Analysis of the transcription of mutation c.434G4A in ALOXE3
using a mini-gene assay. Genomic DNA of patient ISA spanning intron 1 to
exon 5 was cloned and expressed. RNA analysis revealed a shortened
fragment from exon 2 to exon 4 (upper panel). Sequence analysis showed
complete skipping of exon 3 (lower panel). Pa, patient; Co, control; D, DNA
template; N, negative control; M, molecular weight standard.
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ALOXE3 were found in 17 patients each, thus each
representing 6.8% of the cases. We have identified three
new mutations in ALOXE3 and eight new mutations in
ALOX12B in ARCI patients from Germany, Spain, Belgium,
Israel, the United Arab Emirates, and Sri Lanka. Thus our
findings also demonstrate extended allelic heterogeneity of
ARCI.
Surprisingly, we found 6 of 8 mutations in ALOX12B to be
deletions, insertions, or splice site mutations leading to
frameshift, in contrast to the mutations known so far, which
consisted in 21 missense mutations and only 4 mutations
resulting in premature termination codons. The same was
true for ALOXE3, where we found two deletions and a splice
site mutation. Truncating mutations are likely to result in loss
a
b
c d e
Figure 2. Clinical presentation of patients with epidermal lipoxygenase deficiency. (a and b) Clinical presentation of adults: the light scaling (a) and
hyperlinearity of the hands (b) in a patient with mutations in ALOXE3 were reminiscent of ichthyosis vulgaris but the ichthyosis was present at birth, and the
patient showed a mild keratotic lichenification of the overall integument (patient FE3). (c–e) Clinical presentation of children: the keratotic lichenification also
included the elbow fossa and dorsa of the extremities (c, patient FE1; d, FE4). Additionally, there was a peculiar kink of the external ear helix in patient FE4 (e).
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Figure 3. RP-HPLC analysis of the products formed by wild-type or mutant LOX. Homogenates from HEK-293 cells transiently transfected with pcDNA3
constructs containing wild-type or mutant 12R-LOX and eLOX-3 or the b-galactosidase (lacZ) coding region were incubated in TE buffer with (a) 100 mM
arachidonic acid or (b) 50mM 12R-HPETE for 15 minutes at 37 1C. Products were extracted with methanol/dichloromethane, dried under vacuum, redissolved in
methanol/water/acetic acid (82:18:0.01 by volume), injected on a 4 mm YMC-Pack ODS-H80 column, and eluted at 0.5 ml min1. The eluates were monitored
at 235 and 205 nm, respectively. Authentic 12-HETE and 8R-hydroxy-11R,12R-epoxyeicosatrienoc acid (8R,11R(12R)-HepEtrE) were used as standards. The
retention times of 12-HETE and 8R,11R(12R)-HepEtrE were 32.2 and 19.3 minutes, respectively.
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of protein activity. All missense and in-frame mutations found
in either ALOX12B or ALOXE3 were analyzed functionally.
The mutants were properly expressed in HEK 293 cells but
completely lacked enzymatic activity. These results indicate
that ARCI is caused by inactivating mutations in ALOX12B
and ALOXE3 regardless of whether or not the mutant protein
is synthesized.
In contrast to most other studies, the families reported here
were mostly not consanguineous. This is of interest with
regard to the distribution of the mutations in different genes
for ARCI and within a gene. The mutations described here
were distributed throughout the entire genes (Figure 4). There
was a minor focus on exons 9 and 12 in ALOX12B in the
regions encoding the substrate-binding pocket of the enzyme.
However, most mutations were private ones, either hetero-
zygous or homozygous by descent, and no mutation was
found on more than four different chromosomes. In contrast,
only a total of nine different mutations are known in ALOXE3,
three of these described here, although the overall frequency
of mutations is identical in both LOX genes. Our results
reveal that this is due to the high frequency of mutations
p.Arg234X and p.Pro630Leu in eLOX-3. These two mutations
were seen in 10 families described here and 5 previously
reported kindreds (Jobard et al., 2002; Eckl et al., 2005). In
total, p.Arg234X was found on 13 alleles and p.Pro630Leu on
15 alleles in 12 families from Germany, 2 from the Czech
Republic, and 1 from France so far. Microsatellite analysis did
not support a founder effect except in case of the Czech
families with mutation c.700C4T (data not shown). Thus,
p.Arg234X and p.Pro630Leu appear to represent true muta-
tional hotspots. In case of c.700C4T the CG to TG transition
may be due to the spontaneous deamination of 5-methylcy-
tosine in the dinucleotide CpG. This type of mutation often
associates with mutational hotspots and accounts for
approximately 37% of all transitions (Krawczak et al., 1998;
Antonarakis et al., 2000; Cooper, 2002). Moreover, these
data imply that ALOXE3 is at least partly methylated in the
germ lines, which is in accordance with previous observa-
tions (Monk et al., 1987, 1991; Koeberl et al., 1990; Bestor,
1996; Bestor and Tycko, 1996). The high frequency of the
mutation c.1889C4T cannot be explained easily. Again this
is a transition, which is the more common mutation type as
compared to transversions, however, it does not affect a CpG
dinucleotide. Both mutational hotspots in ALOXE3 are
probably due to structural features of the gene beyond its
primary structure.
In concordance to our previous findings (Eckl et al., 2005)
we saw only mild to moderate, light to light-brown scaling
with no or moderate erythema in all patients. In contrast,
patients with severe transglutaminase deficiency caused by
inactivating mutations in TGM1 mostly show a severe
lamellar ichthyosis, often with brown to dark-brown scaling
(Hennies et al., 1998; Oji and Traupe, 2006). The clinical
findings were independent of mutation position and type.
There were some differences between patients with muta-
tions in ALOX12B and those with ALOXE3 mutations.
Patients with mutations in ALOX12B showed a lighter and
more discrete scaling in comparison to an often brownish and
moderately adherent scaling seen in patients with ALOXE3
mutations (Table S1). This finding, scored and averaged over
all body sites, was not significant though using Fisher’s exact
test on a 2 2 table (P¼ 0.067). However, erythema was
significantly more pronounced in patients with ALOX12B
mutations (P¼0.0017). Remarkably, all patients with
ALOX12B mutations showed mild hyperkeratosis of palms
and soles with accentuated palmoplantar creases. Kerato-
derma was absent in 9/12 patients with mutations in
ALOXE3, and the other three only showed a very discrete
palmar or plantar keratosis (P¼ 0.00071). In total, 76% (13/
17) of the patients were born as collodium babies or showed
a partial collodium membrane. Interestingly, 6/8 patients
complained about itching, and 15/17 reported reduced or
completely absent sweating ability.
In summary, we have identified 11 previously unreported
mutations in ALOX12B and ALOXE3 in patients with ARCI.
All the mutations were loss-of-function mutations, either
impairing enzyme activity or ablating protein synthesis, thus
confirming the crucial role played by 12R-LOX and eLOX-3
N C
100
R234X
eLOX-3
12R-LOX
P630L
∗∗
200 300 400 500 600 700
Figure 4. Schematic representation of the domain organization of 12R-LOX and eLOX-3 and survey of known mutations associated with ARCI. The amino-
acid sequences of 12R-LOX and eLOX-3 are very similar to each other. 12R-LOX and eLOX-3 contain an N-terminal b-barrel LH2 domain (dark gray), a
C-terminal catalytic lipoxygenase domain (white) from position 126, and an inserted specific extra domain (black). Putative iron ligands of the active site are
shown in black (Gillmor et al., 1997; Boeglin et al., 1998; Krieg et al., 2001). Mutation sites are represented by arrowheads (upper part: 12R-LOX; lower part:
eLOX-3); missense (white) and truncating (gray) mutations are differentiated. Previously unreported mutations described here are checkered. The two mutational
hotspots in eLOX-3 are marked by asterisks.
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during epidermal barrier formation. In the first analysis of a
large group of patients with ARCI, we have demonstrated that
mutations in ALOX12B or ALOXE3 account for almost 15%
of ARCI cases. Although ALOX12B mutations are distributed
over the gene, there are two significant hotspots for mutations
in ALOXE3. These findings are important for the design of
diagnostic strategies for ARCI and may form the basis of
further studies into the molecular characterization of the
epidermal LOX pathway during epidermal differentiation.
MATERIALS AND METHODS
DNA samples
All patients were diagnosed as having ARCI based on common
clinical criteria. Family history and clinical data were recorded by
specialized dermatologists experienced in keratinization diseases
using a standardized questionnaire that collected data, among
others, on findings at birth, color and form of scales and extent of
erythema on various body sites, and presence or absence of
palmoplantar keratoderma and hyperlinearity on palms and soles
at the time of examination. The study was conducted according to
Declaration of Helsinki principles and approved by the ethical
committee of the Medical Faculty of the University of Cologne.
Blood samples were collected after written informed consent. DNA
was prepared according to standard methods.
Mutation detection
A total of 250 ARCI cases including 15 families described before
(Eckl et al., 2005) were screened for mutations. ALOX12B (GenBank
NM_001139.2) and ALOXE3 (NM_021628.1) consist of 15 exons
each. As described earlier (Eckl et al., 2005), all exons and exon/
intron boundaries were analyzed for mutations by amplifying each
exon and directly sequencing the PCR product using the BigDye
Terminator v.1.1 Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA) on a 3730 DNA Analyzer (Applied Biosystems). Primer
sequences are available upon request.
Haplotype analysis
Microsatellite marker analysis was performed in all families that
showed common mutations in ALOXE3 (c.700C4T or c.1889C4T).
Eight markers covering 14 cM were chosen in and around the
epidermal LOX gene cluster (Krebsova´ et al., 2001; Lugassy et al.,
2008) and amplified in singleplex reactions. Products were pooled,
run on a DNA Analyzer (3730; Applied Biosystems) and analyzed
with GeneMapper software version 3.0 (Applied Biosystems).
Synthesis of mutant recombinant 12R-LOX and eLOX-3
cDNA of human 12R-LOX and eLOX-3 has been cloned in the
eukaryotic expression vector pcDNA3 (Eckl et al., 2005). Site-
directed mutagenesis was performed in the construct for each
missense mutation found using the Site Directed Mutagenesis Kit
(Stratagene, Amsterdam, the Netherlands). Primers were designed
manually following the manufactures’ recommendations. For the
mutation c.1031_1039del9 in ALOXE3 a deletion primer pair was
designed to generate an in-frame deletion of three residues in the
recombinant protein. Transformation was done in SURE II super-
competent cells (Strategene). Clones were analyzed by complete
sequencing using primers T7 and Sp6 and gene-specific primers.
Confirmed mutant clones, wild-type controls and negative control
pcDNA/lacZ were transfected into HEK-293 cells seeded in 10 cm
dishes using the CalPhos method (Clontech, Mountain View, CA).
Cells were harvested 48 hours after transfection, washed and
homogenized by sonication. Cell lysates were used for western blot
analysis and enzymatic assays. All transfection experiments were
done in triplicates.
Western blot analysis
Antibodies against human 12R-LOX and eLOX3 were used as
described (Eckl et al., 2005). Western blotting was performed using
standard techniques after running a 7.5% Laemmli gel. Detection
was done using either rabbit anti-12R-LOX or rabbit anti-eLOX-3
antibody. Anti-b-actin antibody was used as an expression control
for all samples.
Enzyme assay and product analysis
For the 12R-LOX activity assay, homogenates were incubated with
arachidonic acid. For assaying eLOX-3 activity, the homogenates
were incubated with 12R-HPETE. The incubations were terminated
by the addition of sodium formate buffer. The products were
extracted with a modification of the Bligh and Dyer procedure as
described (Chang et al., 1996). The final mixture was centrifuged
and the organic phase was removed and evaporated. The products
were dissolved in ethanol and stored at 70 1C until further analysis.
The products were analyzed by RP-HPLC on a 4 mm YMC-Pack
ODS-H80 column (25cm 0.46 cm; YMC Europe, Schermbeck,
Germany) with a 1 cm guard column using the solvent system of
methanol/water/acetic acid (82:18:0.01 by volume) and a flow rate
of 0.5 ml minute1. Elution was monitored at 205, 235, and 300 nm
on a Bio-Tek Kontron 540 diode array detector.
Splice assay
Genomic DNA constructs spanning exons 2–5 of ALOXE3 from
patient ISA and unaffected control persons were cloned into the
eukaryotic expression vector pcDNA3.1/V5-His TOPO (Invitrogen,
Carlsbad, CA) and transformed into TOP10 competent cells
(Invitrogen). After complete sequencing correct clones were
transfected into HEK-293 cells and total RNA was isolated 48 hours
after transfection. After cDNA synthesis using standard procedures
with oligo(dT) priming, specific PCR was performed with primers
located in exons 2 and 4. Products were extracted from agarose gels
and sequenced.
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SUPPLEMENTARY MATERIAL
Table S1. Summary of clinical features of 20 ARCI patients from 19 families.
(a) Patients with mutations in ALOX12B. (b) Patients with mutations in
ALOXE3.
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Table S2. Summary of mutations in ALOX12B and ALOXE3 identified in
patients with ARCI.
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